ScreenerHero

ARVN Arvinas, Inc.

NAS · US · Healthcare · Biotechnology · arvinas.com
7.450USD+1.92%Mkt Cap: 487.13M $P/E: 28.65

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (P…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap487.13M USD
Enterprise Value-81.93M USD
Revenue (TTM)316.70M USD
Gross Profit307.70M USD
Net Income (TTM)-80.80M USD
Revenue/Share4.75 USD
Last Price7.450 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees246
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)28.65
P/E (Forward)-2.26
PEG—
EV/EBITDA8.28
EV/Revenue-0.26
P/S1.51
P/B0.85
EPS (TTM)0.26
EPS (Forward)-3.23
52W Range
6.9706% of range14.51
52W High14.51 USD
52W Low6.970 USD
Profitability
Gross Margin97.16%
Oper. Margin66.36%
EBITDA Margin-3.13%
Profit Margin-30.77%
ROE-18.63%
ROA-11.26%
Growth
Revenue Growth1014.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-273.80M USD
CapEx (TTM)1.90M USD
FCF Margin-29.84%
FCF Yield-19.40%
Net Debt-559.90M USD
Net Debt/EBITDA56.56
Balance Sheet
Debt/Equity0.02
Current Ratio7.91
Quick Ratio7.54
Book Value/Sh8.61 USD
Cash/Share8.69 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.93 USD
Upside (mean)+87.0%
Target Range6.000 USD – 21.00 USD
6.000+87.0% to mean21.00
# Analysts14
Ownership
Shares Out.65.39M
Float56.81M
Insiders7.80%
Institutions83.94%
Short Interest
Short Ratio6.8d
Short % Float8.89%
Short % Out.7.63%
Shares Short4.99M
Short (prev mo.)4.05M
Technical
SMA 508.603 (-13.4%)
SMA 20010.12 (-26.4%)
Beta1.81
S&P 52W Chg16.45%
Avg Vol (30d)729.29K
Avg Vol (10d)746.69K
Technical Indicators
RSI (14)35.5
MACD-0.3702
MACD Signal-0.3142
MACD Hist.-0.0560
BB Upper9.080 USD
BB Middle7.989 USD
BB Lower6.898 USD
BB Width27.32%
ATR (14)0.3335 USD
Vol Ratio (20d)0.75x